Acute renal failure in a patient with renal carcinoma treated with Temsirolimus;Fracaso renal agudo en un paciente con carcinoma renal tratado con Temsirolimus

Nefrologia

Volumn 29, Issue 6, 2009, Pages 612-

  Benito, Manuel Heras ^a   Fernandez Reyes M J ^a   Rodriguez A ^a   Molina, A ^a   Alvarez Ude F ^a   Esteban, B ^a  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; RAPAMYCIN; TEMSIROLIMUS;

ACUTE KIDNEY FAILURE; CARCINOMA; CASE REPORT; CHEMICALLY INDUCED DISORDER; HUMAN; KIDNEY TUMOR; LETTER; MALE; MIDDLE AGED;

ANTINEOPLASTIC AGENTS; CARCINOMA; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SIROLIMUS;

EID: 77953150275     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.2009.29.6.5463.en.full     Document Type: Letter

References (3)

1. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1387-92.
2. Malizzia LJ, Hsu A. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal carcinoma. Clin J Oncol Nurs 2008;12:639-46.
3. Gerullis H, Bergmann L, Maute L, Eimer C, Otto T. Experiences and practical conclusions concerning Temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol 2009;63:1097-102.